2:55 PM
Oct 08, 2018
 |  BC Extra  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial by 4Q19 of the compound in the indication that will use a different primary endpoint than that of the Phase II trial. CX-8998 is a calcium channel T-type blocker.

On the Phase II trial's primary endpoint, CX-8998 failed to improve tremor severity from baseline to day 28...

Read the full 390 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >